GlassScriptPhysician profile
Amy R Pointon
NPI 1629361357
$8,791.71
in general payments reported to CMS, 2019-2025
32 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $2,244 · 2023: $1,742 · 2024: $2,187 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,634.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,762.26 | 2021-2025 | |
| Janssen Biotech, INC. | $1,349.82 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,248.60 | 2021-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $673.86 | 2022-2025 | Dupixent |
| Genzyme Corporation | $407.39 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.16 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Nestle Healthcare Nutrition INC. | $284.42 | 2021-2023 | |
| Ardelyx, INC. | $172.22 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $169.13 | 2021-2025 | |
| Boston Scientific Corporation | $169.06 | 2024-2025 | Apollo Esg System, Axios |
| Gilead Sciences, INC. | $141.41 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.41 | 2022 | |
| Lilly USA, LLC | $121.13 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $108.93 | 2022-2025 | Linzess |
| Redhill Biopharma INC. | $99.62 | 2021-2023 | Movantik, Aemcolo, Talicia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $74.52 | 2022 | |
| Aimmune Therapeutics, INC. | $74.09 | 2024 | |
| Qol Medical, LLC | $64.29 | 2022-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $62.37 | 2023-2025 | Rebyota, Clenpiq |
| Phathom Pharmaceuticals, INC. | $61.51 | 2024 | Voquezna |
| Pfizer INC. | $58.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $55.88 | 2024 | Bylvay, Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.61 | 2023-2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $20.61 | 2023 | |
| Madrigal Pharmaceuticals | $20.26 | 2024 | Resmetirom |
| Celgene Corporation | $19.17 | 2022 | |
| Ethicon US, LLC | $18.35 | 2022 | |
| Merck Sharp & Dohme LLC | $16.87 | 2022 | |
| Novo Nordisk INC | $15.30 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.87 | 2022 | |
| Exact Sciences Corporation | $12.86 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Pointon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.